Dipeptidyl peptidase-4 (DPP-4) inhibitors have gained extensive importance as effective antidiabetic drugs, in the management of patients with type 2 diabetes mellitus (T2DM). The predominant glucose-lowering effect of the drugs is facilitated by DPP-4 enzyme inhibition, an enzyme that cleaves the incretin hormones glucagon-like peptide 1 and gastric inhibitory polypeptide.1 DPP-4 inhibitors exert multiple nonglycemic actions in the cardiovascular (CV) system, indicating CVsafety and proven CV benefits. Moreover, DPP-4 inhibitors have demonstrated renoprotective effects by reducing the risk of development or progression of albuminuria without affecting other renal outcomes such as the risk of end-stage renal disease.
This has highlighted further interest in the potential use of DPP-4 inhibitors in the management of T2DM. In this regard, Boehringer Ingelheim India and Docplexus have…